Please login to the form below

Not currently logged in
Email:
Password:

Charles Morris appointed chief development officer at ImmunoGen

Previously worked in oncology for Allos, Cephalon and AstraZeneca

Immunogen has appointed Dr Charles Morris as the company's chief development officer.

Dr Morris, who joins from Allos Therapeutics, will oversee all aspects of product development for the US cancer-focused biotech.

Its pipeline includes the investigational compounds IMGN901 - in phase II testing for the treatment of small-cell lung cancer - IMGN853, in phase I for the treatment of ovarian, lung, and other cancers that over-express folate receptor 1, and IMGN529 - in phase I testing for the treatment of non-Hodgkin's lymphoma.

ImmunoGen said it also expects to advance a fourth compound into clinic studies in 2013.

"Charlie has extensive experience leading the strategic development and registration of novel oncology compounds — expertise essential to ImmunoGen with our advancing and expanding product pipeline," said Daniel Junius, president and CEO of the company.

“We are excited to have Charlie joining ImmunoGen at this important time in our transition to being a product development company."

Dr Morris was previously executive VP and chief medical officer at Allos for two years, holding similar responsibilities as to his current role.

Prior to joining Allos, which was acquired in September by Spectrum Pharmaceuticals, he served as VPof  worldwide clinical research at US biopharma company Cephalon, where he helped with the development of oncology drug Treanda (bendamustine).

He has also spent time with AstraZeneca, where his roles included VP, clinical development projects in oncology.

27th November 2012

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics